Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
AnaCardio ABPrivate | 1 asset: 1 Ph 2 | AC01Phase 2 · Heart FailureWeak signal | 30 Jul 2028AC01 · Phase 2 | — | — | — | — |
Angel PharmaceuticalsPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | soquelitinibPhase 3 · Peripheral T-Cell LymphomaWeak signal | 30 Dec 2026soquelitinib · Phase 1 | — | — | — | — |
| 2 assets: 2 approved | Approved assets only | 31 Jan 2027Cenobamate · Phase 2 | — | — | — | — | |
| 1 asset: 1 Ph 1 | Anhui HygeianCells EE001Phase 1 · Heart FailureWeak signal | None on record | — | — | — | — | |
Ankyra Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | Tolododekin AlfaPhase 1 · Non-Small Cell Lung Cancer | Apr 2027Tolododekin Alfa · Phase 1 | — | — | — | — |
Antag TherapeuticsPrivate | 1 asset: 1 Ph 2 | AT-7687Phase 2 · Obesity | Feb 2027AT-7687 · Phase 2 | — | — | — | — |
Anwita Biosciences, Inc.Private | 1 asset: 1 Ph 1 | AWT020Phase 1 · Non-Small Cell Lung Cancer | 30 Apr 2028AWT020 · Phase 1 | — | — | — | — |
AOBiomePrivate | 1 asset: 1 Ph 2 | Nitrosomonas eutropha (B244)Phase 2 · Atopic DermatitisReliable signal | None on record | — | — | — | — |
| 1 asset: 1 approved | Approved assets only | 18 Nov 2027Ropeginterferon alfa-2b (Besremi) · Phase 3 | — | — | — | — | |
Apellis PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | Jul 2027Pegcetacoplan · Phase 3 | — | — | — | — |
AplagonPrivate | 1 asset: 1 Ph 2 | APACPhase 2 · Atherosclerotic Cardiovascular Disease | 30 Jun 2027APAC · Phase 2 | — | — | — | — |
Apogee TherapeuticsPrivate | 3 assets: 1 Ph 2, 2 Ph 1 | ZumilokibartPhase 2 · Atopic Dermatitis | Nov 2026Zumilokibart · Phase 2 | — | $972MJun 2026 | ~16.4 qtrs | $226M |
Apollo TherapeuticsPrivate | 4 assets: 3 Ph 2, 1 Ph 1 | camoteskimabPhase 2 · Atopic DermatitisPartial signal | Jul 2027APL-4098 · Phase 1 | — | — | — | — |
Apotex Inc.Private | 5 assets: 5 approved | Approved assets only | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | AP-472Phase 2 · Parkinson's Disease | 3 Sep 2027AP-472 · Phase 2 | — | — | — | — | |
APRINOIA TherapeuticsPrivate | 1 asset: 1 Ph 1 | APNmAb005Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Araclon Biotech (Grifols)Private | 1 asset: 1 Ph 2 | ABvac40Phase 2 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
| 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — | |
| 1 asset: 1 Ph 2 | BucindololPhase 2 · Heart FailurePartial signal | None on record | — | — | — | — | |
ARCE Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | ARD103Phase 1/2 · Acute Myeloid Leukemia | Oct 2028ARD103 · Phase 1/2 | — | — | — | — |
Arcera Life SciencesPrivate | 1 asset: 1 Ph 3 | EnavogliflozinPhase 3 · Type 2 DiabetesReliable signal | Nov 2027Enavogliflozin · Phase 3 | — | — | — | — |
Areteia TherapeuticsPrivate | 1 asset: 1 Ph 2 | dexpramipexolePhase 2 · Chronic Obstructive Pulmonary DiseaseReliable signal | None on record | — | — | — | — |
AriBioPrivate | 1 asset: 1 Ph 3 | AR1001Phase 3 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Arog Pharmaceuticals, Inc.Private | 1 asset: 1 Ph 3 | CrenolanibPhase 3 · Acute Myeloid LeukemiaReliable signal | None on record | — | — | — | — |
Aromics TherapeuticsPrivate | 1 asset: 1 Ph 1 | AROG4-01Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
AronoraPrivate | 2 assets: 2 Ph 2 | AB002Phase 2 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | — |
Artax BiopharmaPrivate | 1 asset: 1 Ph 2 | AX-158Phase 1/2 · Psoriasis | None on record | — | — | — | — |
Artery TherapeuticsPrivate | 1 asset: 1 Ph 1 | CS6253Phase 1 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Asher Biotherapeutics, Inc.Private | 1 asset: 1 Ph 1 | Etakafusp alfaPhase 1 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
Ashibio IncPrivate | 1 asset: 1 Ph 3 | AndecaliximabPhase 2/3 · Fibrodysplasia Ossificans Progressiva | Dec 2028Andecaliximab · Phase 1/2 | — | — | — | — |
AskBioPrivate | 1 asset: 1 Ph 2 | Ametefgene parvecPhase 2 · Parkinson's DiseaseWeak signal | 30 Apr 2028Ametefgene parvec · Phase 2 | — | — | — | — |
Aspen NeurosciencePrivate | 1 asset: 1 Ph 1 | SasineprocelPhase 1 · Parkinson's Disease | 30 Mar 2027Sasineprocel · Phase 1 | — | — | — | — |
Astex Pharmaceuticals, Inc.Private | 1 asset: 1 approved | Approved assets only | 1 Nov 2027Capivasertib · Phase 3 | — | — | — | — |
AtaiBeckley Inc.Private | 3 assets: 3 Ph 2 | BPL-003 (mebufotenin benzoate)Phase 2 · Major Depressive DisorderPartial signal | None on record | — | $169MJun 2026 | ~5.2 qtrs | $76M |
Atavistik Bio, Inc.Private | 1 asset: 1 Ph 1 | ATV-1601Phase 1 · HR+/HER2- Metastatic Breast Cancer | Dec 2027ATV-1601 · Phase 1/2 | — | — | — | — |
Athos TherapeuticsPrivate | 1 asset: 1 Ph 2 | ATH-063Phase 2 · Ulcerative ColitisWeak signal | 14 Dec 2028ATH-063 · Phase 2 | — | — | — | — |
Atom TherapeuticsPrivate | 2 assets: 2 Ph 2 | ABP-745Phase 2 · Atherosclerotic Cardiovascular Disease | 31 Oct 2027Lingdolinurad · Phase 2 | — | — | — | — |
Aulos Bioscience, Inc.Private | 1 asset: 1 Ph 2 | ImneskibartPhase 1/2 · Non-Small Cell Lung Cancer | 28 Feb 2027Imneskibart · Phase 1/2 | — | — | — | — |
Auricula Biosciences Inc.Private | 1 asset: 1 Ph 2 | WEF-001Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2028WEF-001 · Phase 1/2 | — | — | — | — |
| 2 assets: 1 Ph 2, 1 Ph 1 | EmavusertibPhase 2 · Acute Myeloid Leukemia | Jan 2027AUR107 · Phase 1 | — | — | — | — | |
Auron Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | AUTX-703Phase 1 · Acute Myeloid Leukemia | Apr 2027AUTX-703 · Phase 1 | — | — | — | — |
AusperBioPrivate | 1 asset: 1 Ph 2 | AHB-171Phase 2 · Chronic Hepatitis B | 8 Oct 2027AHB-171 · Phase 1 | — | — | — | — |
Autobahn TherapeuticsPrivate | 1 asset: 1 Ph 2 | ElunetiromPhase 2 · Major Depressive Disorder | None on record | — | — | — | — |
Avanzanite BiosciencePrivate | 1 asset: 1 approved | Approved assets only | Mar 2029Mitapivat · Phase 3 | — | — | — | — |
AvenCell Europe GmbHPrivate | 1 asset: 1 Ph 1 | Allo-RevCAR01-TPhase 1 · Acute Myeloid Leukemia | May 2027Allo-RevCAR01-T · Phase 1 | — | — | — | — |
Avenzo Therapeutics, Inc.Private | 3 assets: 3 Ph 2 | AVZO-021Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 31 Jan 2028AVZO-021 · Phase 1/2 | — | — | — | — |
Avere TherapeuticsPrivate | 1 asset: 1 Ph 2 | HS-20118Phase 2 · Psoriasis | 25 Dec 2026HS-20118 · Phase 1 | — | — | — | — |
Avistone BiotechnologyPrivate | 3 assets: 2 Ph 3, 1 Ph 2 | VebreltinibPhase 3 · Non-Small Cell Lung CancerWeak signal | Nov 2026Andamertinib · Phase 2 | — | — | — | — |
Avobis BioPrivate | 1 asset: 1 Ph 2 | AVB-114Phase 2 · Crohn's DiseasePartial signal | None on record | — | — | — | — |
Axon NeurosciencePrivate | 1 asset: 1 Ph 2 | AADvac1Phase 2 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Ayrmid Ltd.Private | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Azurity PharmaceuticalsPrivate | 10 assets: 10 approved | Approved assets only | Sep 2027Zonisamide (Zonisade) · Approved | — | — | — | — |
Bambusa TherapeuticsPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | BBT002Phase 1/2 · Chronic Obstructive Pulmonary Disease | 31 Dec 2026BBT002 · Phase 1 | — | — | — | — |
| 2 assets: 2 Ph 1 | NK520Phase 1 · Acute Myeloid LeukemiaWeak signal | Jun 2027NK510 · Phase 1 | — | — | — | — | |
BCWorld PharmPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Beeline MedicinesPrivate | 3 assets: 2 Ph 2, 1 Ph 1 | LomedeucitinibPhase 2 · PsoriasisPartial signal | Apr 2030Afimetoran · Phase 2/3 | — | — | — | — |
| 1 asset: 1 Ph 2 | BioTTT001Phase 1/2 · Non-Small Cell Lung Cancer | 31 Jul 2027BioTTT001 · Phase 1/2 | — | — | — | — | |
Beijing BiotechPrivate | 5 assets: 5 Ph 2 | Beijing Biotech anti-CD19 CAR-TPhase 1/2 · Systemic Lupus Erythematosus | 14 Feb 2027Dual-target Car-nk Cells · Phase 1/2 | — | — | — | — |
Beijing Dongfang BiotechPrivate | 1 asset: 1 Ph 3 | exendin-4 Fc fusion (JY09)Phase 3 · Type 2 Diabetes | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | GW117Phase 2 · Major Depressive DisorderPartial signal | None on record | — | — | — | — | |
| 3 assets: 3 Ph 1 | IM21 CAR-T cellsPhase 1 · Multiple MyelomaWeak signal | None on record | — | — | — | — | |
Beijing Inno MedicinePrivate | 1 asset: 1 Ph 2 | YN001Phase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | 31 Jul 2027YN001 · Phase 2 | — | — | — | — |
Beijing Joekai BiotechnologyPrivate | 1 asset: 1 Ph 2 | 50561Phase 2 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
| 2 assets: 1 Ph 3, 1 Ph 2 | Obinutuzumab beta (Bejescin)Phase 3 · Systemic Lupus Erythematosus | Dec 2027MBS314 · Phase 1/2 | — | — | — | — | |
Beijing Northland BiotechPrivate | 1 asset: 1 Ph 3 | NL003Phase 3 · Atherosclerotic Cardiovascular Disease | None on record | — | $17MSep 2025 | Ended Aug 2026 | $6.1M |
Beijing QL BiopharmaceuticalPrivate | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | zovaglutidePhase 3 · ObesityReliable signal | 3 Dec 2026zovaglutide · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 1 | mulberry twig alkaloidsPhase 1 · ObesityWeak signal | None on record | — | — | — | — | |
| 1 asset: 1 Ph 3 | LecankitugPhase 3 · Psoriasis | None on record | — | — | — | — | |
Belenos BiosciencesPrivate | 1 asset: 1 Ph 2 | CM512Phase 2 · Atopic DermatitisWeak signal | 21 Jul 2027CM512 · Phase 2 | — | — | — | — |
Benethera BiotechnologyPrivate | 1 asset: 1 Ph 1 | BDHK-2009Phase 1 · Ulcerative Colitis | None on record | — | — | — | — |
Beta Pharma, Inc.Private | 2 assets: 1 Ph 3, 1 Ph 2 | RezivertinibPhase 3 · Non-Small Cell Lung CancerReliable signal | None on record | — | — | — | — |
BeyondBioPrivate | 1 asset: 1 Ph 2 | BEY2153Phase 2 · Alzheimer's DiseasePartial signal | Jul 2028BEY2153 · Phase 2 | — | — | — | — |
BIAL - PortelaPrivate | 3 assets: 2 approved, 1 Ph 2 | ZamicastatPhase 2 · Pulmonary Arterial HypertensionWeak signal | None on record | — | — | — | — |
BiocadPrivate | 8 assets: 7 Ph 3, 1 Ph 1 | AcellbiaPhase 3 · Rheumatoid ArthritisReliable signal | Jul 2028Torutamig · Phase 3 | — | — | — | — |
BioCity BiopharmaceuticsPrivate | 1 asset: 1 Ph 3 | SC0062Phase 3 · Chronic Kidney Disease | 31 Dec 2026SC0062 · Phase 3 | — | — | — | — |
BiocodexPrivate | 1 asset: 1 approved | Approved assets only | Aug 2030Stiripentol · Phase 3 | — | — | — | — |
Biocon BiologicsPrivate | 3 assets: 2 approved, 1 Ph 1 | Bmab1700Phase 1 | 16 Aug 2027Bmab1700 · Phase 1 | — | — | — | — |
BioEclipse TherapeuticsPrivate | 1 asset: 1 Ph 1 | CRX100Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Bioeq AGPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
BioGenCellPrivate | 1 asset: 1 Ph 2 | BGC101Phase 1/2 · Atherosclerotic Cardiovascular Disease | None on record | — | — | — | — |
| 1 asset: 1 Ph 1 | Microlyvaq™Phase 1 · Non-Small Cell Lung Cancer | 2 Feb 2028Microlyvaq™ · Phase 1 | — | — | — | — | |
BioLitePrivate | 1 asset: 1 Ph 2 | PDC-1421Phase 2 · Major Depressive DisorderPartial signal | 28 Feb 2028PDC-1421 · Phase 1/2 | — | — | — | — |
Biolitec PharmaPrivate | 1 asset: 1 other | Aflibercept (Eyluxvi)Age-Related Macular Degeneration | None on record | — | — | — | — |
Biomed IndustriesPrivate | 1 asset: 1 Ph 2 | NA-931Phase 2 · ObesityPartial signal | 15 Aug 2027NA-931 · Phase 2 | — | — | — | — |
Bionyra PharmaPrivate | 1 asset: 1 Ph 1 | TL-003Phase 1 · Ulcerative Colitis | Apr 2027TL-003 · Phase 1 | — | — | — | — |
BiopeuticsPrivate | 1 asset: 1 Ph 3 | alprostadilPhase 3 · Heart Failure | Nov 2029alprostadil · Phase 3 | — | — | — | — |
BioprojetPrivate | 1 asset: 1 approved | Approved assets only | Apr 2027Pitolisant (Wakix) · Phase 3 | — | — | — | — |
| 2 assets: 2 other | BCMA-CART (Bioray Laboratories)Multiple Myeloma | 15 Mar 2027BRL-305 · Phase na | — | — | — | — | |
BiosionPrivate | 2 assets: 1 Ph 2, 1 other | BosakitugPhase 2 · Atopic DermatitisWeak signal | None on record | — | — | — | — |
Biotest AGPrivate | 1 asset: 1 Ph 3 | Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)Phase 3 | None on record | — | — | — | — |
BioTheryX, Inc.Private | 1 asset: 1 Ph 1 | BTX-9341Phase 1 · HR+/HER2- Metastatic Breast Cancer | 30 Sep 2027BTX-9341 · Phase 1 | — | — | — | — |
Biotroy TherapeuticsPrivate | 1 asset: 1 Ph 2 | BT02Phase 1/2 · Non-Small Cell Lung Cancer | Mar 2027BT02 · Phase 1 | — | — | — | — |
Bluefin BiomedicinePrivate | 1 asset: 1 Ph 3 | BFB759Phase 2/3 · Hidradenitis Suppurativa | 28 Feb 2027BFB759 · Phase 2 | — | — | — | — |
Blueprint MedicinesPrivate | 2 assets: 1 approved, 1 Ph 2 | BLU-924Phase 1/2 · Non-Small Cell Lung Cancer | 30 Jul 2027Pralsetinib · Approved | — | — | — | — |
BlueRock TherapeuticsPrivate | 1 asset: 1 Ph 3 | Bemdaneprocel (MSK-DA01)Phase 3 · Parkinson's DiseaseWeak signal | Oct 2028Bemdaneprocel (MSK-DA01) · Phase 3 | — | — | — | — |
BlueSphere BioPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | BSB-1001Phase 1/2 · Acute Myeloid Leukemia | None on record | — | — | — | — |
BnH Research (Korea)Private | 1 asset: 1 Ph 1 | BnH-015BPhase 1 · Alzheimer's Disease | None on record | — | — | — | — |
Boehringer IngelheimPrivate | 39 assets: 17 approved, 9 Ph 3, 8 Ph 2, 4 Ph 1, 1 other | PramipexoleUS approval withdrawn · Parkinson's DiseasePartial signal | 8 Dec 2026survodutide · Phase 1 | — | — | — | — |
Boston OncologyPrivate | 2 assets: 2 Ph 3 | BireociclibPhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | None on record | — | — | — | — |
BrexogenPrivate | 1 asset: 1 Ph 1 | BxC-I17ePhase 1 · Atopic Dermatitis | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.